Patent directory · USPTO A61K / A61P
Patents matching “Sangamo Therapeutics, Inc.”
106 pharma patents match "Sangamo Therapeutics, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.
Quick answer
This filtered view shows 106 pharmaceutical patents matching "Sangamo Therapeutics, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.
Patent results
-
US 10907175
Isolated human cell with an inactivated glucocorticoid receptor gene
granted -
US 10889834
Methods and compositions for enhancing targeted transgene integration
granted -
US 10888589
Modulation of stem cells using zinc finger proteins
granted -
US 10883119
Methods and compositions for delivery of biologics
granted -
US 10857203
Methods and compositions for treating Huntington's disease
granted -
US 10828376
Liver-specific constructs and methods of use thereof
granted -
US 10822599
Compositions for linking DNA-binding domains and cleavage domains
granted -
US 10808020
Nuclease-mediated regulation of gene expression
granted -
US 10724020
Compositions for linking DNA-binding domains and cleavage domains
granted -
US 10717993
Methods and compositions for increased transgene expression
granted -
US 10689717
Methods and compositions for targeted single-stranded cleavage and targeted integration
granted -
US 10675302
Methods and compositions for targeted cleavage and recombination
granted -
US 10648001
Method of treating mucopolysaccharidosis type I or II
granted -
US 10646543
Methods and compositions for treating trinucleotide repeat disorders
granted -
US 10639383
Methods and compositions for engineering immunity
granted -
US 10619154
Nuclease-mediated regulation of gene expression
granted -
US 10604771
Delivery methods and compositions for nuclease-mediated genome engineering
granted -
US 10563184
Regulation of gene expression using engineered nucleases
granted -
US 10538787
Compositions for linking DNA-binding domains and cleavage domains
granted -
US 10500229
Targeted disruption of the MHC cell receptor
granted -
US 10494648
Delivery methods and compositions for nuclease-mediated genome engineering
granted -
US 10471123
Methods and compositions for treating Huntington's disease
granted -
US 10450585
Delivery methods and compositions for nuclease-mediated genome engineering
granted -
US 10435677
Genetically modified human cell with a corrected mutant sickle cell mutation
granted